0001360214 2021-01-01 2021-06-30 0001360214 HROW:CommonStock0.001ParValuePerShareMember 2021-01-01 2021-06-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-01-01 2021-06-30 0001360214 2021-08-09 0001360214 2021-06-30 0001360214 2020-12-31 0001360214 HROW:SurfaceOphthalmicsMember 2021-06-30 0001360214 HROW:SurfaceOphthalmicsMember 2020-12-31 0001360214 HROW:MeltPharmaceuticalsMember 2021-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-12-31 0001360214 2021-04-01 2021-06-30 0001360214 2020-04-01 2020-06-30 0001360214 2020-01-01 2020-06-30 0001360214 HROW:ProductSalesNetMember 2021-04-01 2021-06-30 0001360214 HROW:ProductSalesNetMember 2020-04-01 2020-06-30 0001360214 HROW:ProductSalesNetMember 2021-01-01 2021-06-30 0001360214 HROW:ProductSalesNetMember 2020-01-01 2020-06-30 0001360214 HROW:OtherRevenuesMember 2021-04-01 2021-06-30 0001360214 HROW:OtherRevenuesMember 2020-04-01 2020-06-30 0001360214 HROW:OtherRevenuesMember 2021-01-01 2021-06-30 0001360214 HROW:OtherRevenuesMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2021-04-01 2021-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-04-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2021-01-01 2021-06-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-01-01 2020-06-30 0001360214 HROW:SurfaceOphthalmicsMember 2021-04-01 2021-06-30 0001360214 HROW:SurfaceOphthalmicsMember 2020-04-01 2020-06-30 0001360214 HROW:SurfaceOphthalmicsMember 2021-01-01 2021-06-30 0001360214 HROW:SurfaceOphthalmicsMember 2020-01-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2021-04-01 2021-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-04-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2021-01-01 2021-06-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-01-01 2020-06-30 0001360214 us-gaap:PreferredStockMember 2020-03-31 0001360214 us-gaap:CommonStockMember 2020-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001360214 us-gaap:RetainedEarningsMember 2020-03-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-03-31 0001360214 2020-03-31 0001360214 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001360214 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-04-01 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001360214 us-gaap:PreferredStockMember 2020-06-30 0001360214 us-gaap:CommonStockMember 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-06-30 0001360214 2020-06-30 0001360214 us-gaap:PreferredStockMember 2021-03-31 0001360214 us-gaap:CommonStockMember 2021-03-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001360214 us-gaap:RetainedEarningsMember 2021-03-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-03-31 0001360214 us-gaap:NoncontrollingInterestMember 2021-03-31 0001360214 2021-03-31 0001360214 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001360214 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001360214 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-04-01 2021-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001360214 us-gaap:PreferredStockMember 2021-06-30 0001360214 us-gaap:CommonStockMember 2021-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001360214 us-gaap:RetainedEarningsMember 2021-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-06-30 0001360214 us-gaap:PreferredStockMember 2019-12-31 0001360214 us-gaap:CommonStockMember 2019-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001360214 us-gaap:RetainedEarningsMember 2019-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2019-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2019-12-31 0001360214 2019-12-31 0001360214 us-gaap:PreferredStockMember 2020-01-01 2020-06-30 0001360214 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-01-01 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-06-30 0001360214 us-gaap:PreferredStockMember 2020-12-31 0001360214 us-gaap:CommonStockMember 2020-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001360214 us-gaap:RetainedEarningsMember 2020-12-31 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2020-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2020-12-31 0001360214 us-gaap:PreferredStockMember 2021-01-01 2021-06-30 0001360214 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001360214 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001360214 HROW:TotalHarrowHealthIncStockholdersEquityMember 2021-01-01 2021-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-04-01 2021-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-01-01 2021-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2021-06-30 0001360214 srt:MaximumMember HROW:EtonPharmaceuticalsIncMember 2021-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-04-01 2021-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-01-01 2021-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2021-06-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-12-31 0001360214 HROW:SurfacePharmaceuticalsIncMember 2021-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2021-04-01 2021-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-04-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2021-01-01 2021-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-06-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-12-31 0001360214 HROW:CommissionsMember 2021-04-01 2021-06-30 0001360214 HROW:CommissionsMember 2020-04-01 2020-06-30 0001360214 HROW:CommissionsMember 2021-01-01 2021-06-30 0001360214 HROW:CommissionsMember 2020-01-01 2020-06-30 0001360214 us-gaap:LicenseMember 2021-04-01 2021-06-30 0001360214 us-gaap:LicenseMember 2020-04-01 2020-06-30 0001360214 us-gaap:LicenseMember 2021-01-01 2021-06-30 0001360214 us-gaap:LicenseMember 2020-01-01 2020-06-30 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2021-06-30 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2020-12-31 0001360214 srt:MinimumMember us-gaap:PatentsMember 2021-01-01 2021-06-30 0001360214 srt:MaximumMember us-gaap:PatentsMember 2021-01-01 2021-06-30 0001360214 us-gaap:PatentsMember 2021-06-30 0001360214 HROW:LicensesMember 2021-01-01 2021-06-30 0001360214 HROW:LicensesMember 2021-06-30 0001360214 us-gaap:TrademarksMember 2021-01-01 2021-06-30 0001360214 us-gaap:TrademarksMember 2021-06-30 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-06-30 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2021-06-30 0001360214 us-gaap:TradeNamesMember 2021-01-01 2021-06-30 0001360214 us-gaap:TradeNamesMember 2021-06-30 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2021-01-01 2021-06-30 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2021-01-01 2021-06-30 0001360214 HROW:NonCompetitionClauseMember 2021-06-30 0001360214 HROW:StatePharmacyLicensesMember 2021-01-01 2021-06-30 0001360214 HROW:StatePharmacyLicensesMember 2021-06-30 0001360214 us-gaap:PatentsMember 2021-04-01 2021-06-30 0001360214 us-gaap:PatentsMember 2020-04-01 2020-06-30 0001360214 us-gaap:PatentsMember 2021-01-01 2021-06-30 0001360214 us-gaap:PatentsMember 2020-01-01 2020-06-30 0001360214 HROW:LicensesMember 2021-04-01 2021-06-30 0001360214 HROW:LicensesMember 2020-04-01 2020-06-30 0001360214 HROW:LicensesMember 2020-01-01 2020-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2021-04-01 2021-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-04-01 2020-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-06-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-06-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-04-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-05-01 2021-05-31 0001360214 us-gaap:InvestorMember HROW:Sec8.625SeniorNotesDue2026Member 2021-04-30 0001360214 us-gaap:InvestorMember HROW:Sec8.625SeniorNotesDue2026Member 2021-04-01 2021-04-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-06-01 2021-06-30 0001360214 us-gaap:InvestorMember HROW:Sec8.625SeniorNotesDue2026Member 2021-06-30 0001360214 us-gaap:InvestorMember HROW:Sec8.625SeniorNotesDue2026Member 2021-06-01 2021-06-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-06-30 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-04-01 2021-04-30 0001360214 2026-02-01 2026-02-28 0001360214 HROW:Sec8.625SeniorNotesDue2026Member 2021-01-01 2021-06-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 srt:MinimumMember HROW:TermLoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember us-gaap:BaseRateMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-01 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2021-04-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2021-04-01 2021-04-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2021-04-01 2021-06-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2021-01-01 2021-06-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2020-04-01 2020-06-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2020-01-01 2020-06-30 0001360214 HROW:SWKFundingLLCMember 2021-04-30 0001360214 us-gaap:DeferredLossOnEarlyExtinguishmentOfDebtMember HROW:SWKFundingLLCMember 2021-04-01 2021-06-30 0001360214 HROW:SWKFundingLLCMember 2021-01-01 2021-06-30 0001360214 HROW:BusinessLoanAgreementMember 2020-04-30 0001360214 HROW:SanDiegoMember 2021-06-30 0001360214 HROW:SanDiegoMember 2021-01-01 2021-06-30 0001360214 HROW:LedgewoodMember 2021-06-30 0001360214 HROW:LedgewoodMember 2021-01-01 2021-06-30 0001360214 HROW:LedgewoodMember HROW:AdditionalSquareFootageOfLeaseMember 2021-06-30 0001360214 HROW:LedgewoodMember HROW:AdditionalSquareFootageOfLeaseMember 2021-06-01 2021-06-30 0001360214 HROW:NashvilleMember 2021-06-30 0001360214 HROW:NashvilleMember 2021-01-01 2021-06-30 0001360214 stpr:NJ 2021-05-31 0001360214 stpr:NJ 2021-05-01 2021-05-31 0001360214 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0001360214 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0001360214 HROW:SeriesBCumulativePreferredStockRedeemedMember 2021-05-01 2021-05-31 0001360214 HROW:SeriesBCumulativePreferredStockRedeemedMember 2021-05-31 0001360214 HROW:SeriesBCumulativePreferredStockRedeemedMember 2021-06-30 0001360214 HROW:SeriesBCumulativePreferredStockRedeemedMember 2021-01-01 2021-06-30 0001360214 HROW:SeriesBCumulativePreferredStockRedeemedMember 2021-04-01 2021-06-30 0001360214 us-gaap:WarrantMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001360214 us-gaap:WarrantMember us-gaap:CommonStockMember 2021-06-30 0001360214 srt:MinimumMember us-gaap:WarrantMember us-gaap:CommonStockMember 2021-06-30 0001360214 srt:MaximumMember us-gaap:WarrantMember us-gaap:CommonStockMember 2021-06-30 0001360214 us-gaap:OptionMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001360214 us-gaap:OptionMember us-gaap:CommonStockMember 2021-06-30 0001360214 srt:MinimumMember us-gaap:OptionMember us-gaap:CommonStockMember 2021-06-30 0001360214 srt:MaximumMember us-gaap:OptionMember us-gaap:CommonStockMember 2021-06-30 0001360214 us-gaap:CommonStockMember 2020-06-01 2020-06-30 0001360214 HROW:MarkLBaumMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001360214 HROW:MarkLBaumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001360214 HROW:AndrewRBollMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001360214 HROW:AndrewRBollMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2021-06-30 0001360214 HROW:StockOptionPlanOneMember 2020-12-31 0001360214 HROW:StockOptionPlanOneMember 2021-01-01 2021-06-30 0001360214 HROW:StockOptionPlanOneMember 2021-06-30 0001360214 HROW:StockOptionPlanMember 2021-06-30 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2020-01-01 2020-12-31 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2021-01-01 2021-06-30 0001360214 HROW:OptionsEmployeesMember 2021-01-01 2021-06-30 0001360214 HROW:RangeOneMember 2021-01-01 2021-06-30 0001360214 HROW:RangeOneMember 2021-06-30 0001360214 HROW:RangeTwoMember 2021-01-01 2021-06-30 0001360214 HROW:RangeTwoMember 2021-06-30 0001360214 HROW:RangeThreeMember 2021-01-01 2021-06-30 0001360214 HROW:RangeThreeMember 2021-06-30 0001360214 HROW:RangeFourMember 2021-01-01 2021-06-30 0001360214 HROW:RangeFourMember 2021-06-30 0001360214 HROW:StockOptionPlanMember 2021-01-01 2021-06-30 0001360214 HROW:StockOptionPlanMember 2021-04-01 2021-06-30 0001360214 HROW:EmployeesMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0001360214 HROW:UnvestedRSUMember 2021-06-30 0001360214 HROW:UnvestedRSUMember 2021-01-01 2021-06-30 0001360214 HROW:UnvestedRSUMember 2021-04-01 2021-06-30 0001360214 us-gaap:WarrantMember 2020-12-31 0001360214 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001360214 us-gaap:WarrantMember 2021-06-30 0001360214 HROW:LenderWarrantsMember 2021-01-01 2021-06-30 0001360214 HROW:LenderWarrantsMember 2021-06-30 0001360214 HROW:SubsidiaryStockOptionPlanMember 2021-04-01 2021-06-30 0001360214 HROW:SubsidiaryStockOptionPlanMember 2021-01-01 2021-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2021-04-01 2021-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2021-01-01 2021-06-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:EmployeesResearchAndDevelopmentMember 2021-04-01 2021-06-30 0001360214 HROW:EmployeesMember HROW:EmployeesResearchAndDevelopmentMember 2020-04-01 2020-06-30 0001360214 HROW:EmployeesMember HROW:EmployeesResearchAndDevelopmentMember 2021-01-01 2021-06-30 0001360214 HROW:EmployeesMember HROW:EmployeesResearchAndDevelopmentMember 2020-01-01 2020-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2021-04-01 2021-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2021-01-01 2021-06-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 srt:DirectorMember HROW:ConsultantsSellingGeneralAndAdministrativeMember 2021-04-01 2021-06-30 0001360214 srt:DirectorMember HROW:ConsultantsSellingGeneralAndAdministrativeMember 2020-04-01 2020-06-30 0001360214 srt:DirectorMember HROW:ConsultantsSellingGeneralAndAdministrativeMember 2021-01-01 2021-06-30 0001360214 srt:DirectorMember HROW:ConsultantsSellingGeneralAndAdministrativeMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:SecondPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:FinalPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember 2021-04-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember 2021-01-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-04-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-01-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2021-04-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2021-01-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2021-04-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2021-01-01 2021-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-04-01 2020-06-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-01-01 2020-06-30 0001360214 HROW:EyepointCommercialAllianceAgreementMember 2021-04-01 2021-06-30 0001360214 HROW:EyepointCommercialAllianceAgreementMember 2021-01-01 2021-06-30 0001360214 srt:MinimumMember HROW:SalesAndMarketingAgreementsMember 2021-01-01 2021-06-30 0001360214 srt:MaximumMember HROW:SalesAndMarketingAgreementsMember 2021-01-01 2021-06-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2021-04-01 2021-06-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2021-01-01 2021-06-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2020-04-01 2020-06-30 0001360214 HROW:SalesAndMarketingAgreementsMember 2020-01-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2021-04-01 2021-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2021-01-01 2021-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-04-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-01-01 2020-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2021-06-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-06-30 0001360214 HROW:LicenseAgreementMember HROW:MayfieldPharmaceuticalsMember 2021-05-01 2021-05-31 0001360214 HROW:AssetPurchaseAgreementMember HROW:MayfieldPharmaceuticalsMember 2021-05-01 2021-05-31 0001360214 HROW:StoweLicenseAgreementMember HROW:MayfieldPharmaceuticalsMember 2021-05-01 2021-05-31 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2021-04-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2021-04-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember 2021-04-01 2021-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2021-04-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2021-01-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2021-01-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember 2021-01-01 2021-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember 2020-04-01 2020-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:AssetSalesAndImpairmentsNetMember 2020-04-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:ImprimisRxMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember 2020-01-01 2020-06-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001360214 us-gaap:OperatingSegmentsMember HROW:AssetSalesAndImpairmentsNetMember 2020-01-01 2020-06-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-06-30 0001360214 HROW:TwoProductConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-04-01 2021-06-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2021-04-01 2021-06-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2021-01-01 2021-06-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2020-04-01 2020-06-30 0001360214 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember HROW:ThreeMainSuppliersMember 2020-01-01 2020-06-30 0001360214 us-gaap:SubsequentEventMember HROW:SinteticaAgreementMember 2021-07-01 2021-07-31 0001360214 HROW:DueWithinThirtyDaysMember us-gaap:SubsequentEventMember HROW:SinteticaAgreementMember 2021-07-01 2021-07-31 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001360214 false --12-31 Q2

10-Q true 2021-06-30 2021 false 001-35814 Harrow Health, Inc. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Common Stock, $0.001 par value per share HROW NASDAQ 8.625% Senior Notes due 2026 HROWL NASDAQ Yes Yes Non-accelerated Filer true false false 26893896

200000

72851000

4301000

12209000

28455000

3710000

2662000

3903000

3962000

801000

751000

93474000

40131000

4937000

4453000

4747000

6799000

1882000

1939000

1314000

1594000

2506000

332000

106966000

57474000

5207000

3932000

2388000

2315000

56000

66000

1259000

2639000

485000

580000

8000

8144000

10799000

4695000

6652000

14000

17000

800000

708000

71265000

11670000

84118000

30646000

0.001

50000000

26893896

25749875

27000

26000

102837000

104557000

-79661000

-77400000

23203000

27183000

-355000

22848000

26828000

106966000

57474000

17297000

8049000

32245000

19859000

837000

11000

1332000

18000

18134000

8060000

33577000

19877000

4417000

3204000

8187000

6830000

13717000

4856000

25390000

13047000

9123000

6954000

17287000

15370000

425000

749000

1017000

1152000

363000

9548000

8066000

18304000

16885000

4169000

-3210000

7086000

-3838000

-1314000

-505000

-1827000

-1065000

-477000

-690000

-947000

-1236000

-465000

-599000

-1314000

-938000

-3584000

4725000

-6419000

-6125000

-756000

1967000

-51000

19000

-51000

19000

-6647000

2950000

-9347000

-9345000

-2478000

-260000

-2261000

-13183000

-23000

-39000

-2478000

-237000

-2261000

-13144000

472000

-2950000

-237000

-2733000

-13144000

-0.11

-0.01

-0.10

-0.51

26736970

25893629

26379943

25867478

25618918

26000

102261000

-86950000

15337000

-309000

15028000

253

30000

83000

545000

-237000

-23000

-260000

25649171

26000

102889000

-87187000

15728000

-332000

15396000

25983676

26000

105382000

-77183000

28225000

-355000

27870000

5312

21000

311369

977500

1000

-1000

-383961

-3171000

440000 10655000 10655000 10655000

-440000

-11000000

127000

1078000

-2478000

26893896

27000

102837000

-79661000

23203000

-355000

22848000

25526931

26000

101728000

-74043000

27711000

-293000

27418000

253

91987

30000

83000

1078000

-13144000

-39000

-13183000

25649171

26000

102889000

-87187000

15728000

-332000

15396000

25749875

26000

104557000

-77400000

27183000

-355000

26828000

16613

48000

311369

1207500

1000

-1000

-391461

-3228000

440000 10655000 10655000 10655000

-440000

-11000000

127000

1933000

-2261000

26893896

27000

102837000

-79661000

23203000

-355000

22848000

-2261000

-13183000

876000

913000

79000 88000 299000 341000

36000

302000

288000

243000

1967000 -6419000 -6125000 -1314000 -938000 -947000 -1236000

-5000

348000

363000

-706000

83000

1933000

1078000

1084000

311000

-59000

540000

85000

25000

1026000

-2253000

73000

1052000

-10000

-4000

8648000

-3201000

9827000

22000

74000

1360000

536000

8445000

-610000

3000

71073000

15961000

1967000

1000000

3228000

48000

10655000 11000000

127000

51457000

2964000

68550000

-847000

4301000

4949000

72851000

4102000

72651000 3902000 200000 200000 72851000 4102000

788000

408000

41000 1753000

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) specializes in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns one of the nation’s leading ophthalmology-focused pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has non-controlling equity positions in Surface Ophthalmics, Inc. (“Surface”) and Melt Pharmaceuticals, Inc. (“Melt”), both companies that began as subsidiaries of Harrow. In 2020, Harrow created Visionology, Inc. (“Visionology”), which recently launched an online eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Harrow consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheets at June 30, 2021 and December 31, 2020 and the condensed consolidated statements of operations, stockholders’ equity and cash flows for the periods ended June 30, 2021 and 2020 include our accounts and those of our wholly owned subsidiaries, as well as our majority owned subsidiaries Mayfield Pharmaceuticals, Inc. and Stowe Pharmaceuticals, Inc.

The Company consolidates subsidiaries in which it holds and/or controls, directly or indirectly, more than 50% of the voting rights.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the six months ended June 30, 2021 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations. Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information of our operating segments. The Company has identified two operating segments as reportable segments. See Note 16 for more information regarding the Company’s reportable segments. Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interest that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each component of other income or loss.</td></tr> </table> Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period. Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common equivalent shares (using the treasury stock or “if converted” method) from stock options, unvested restricted stock units (“RSUs”) and warrants were 4,121,398 and 5,414,504 at June 30, 2021 and 2020, respectively. For the three and six months ended June 30, 2021 and 2020, the common equivalent shares are excluded in the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at June 30, 2021 and 2020 was 235,973 and 251,746, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the three and six months ended June 30, 2021 and 2020: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49F_20210401__20210630_zITFYKgXI2ji" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200401__20200630_zbnXl9ZnZq5l" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49C_20210101__20210630_zwYuglV9O3Ql" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200101__20200630_zTu58KMR8hA5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Six Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 12pt">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr id="xdx_40A_ecustom--NetIncomeLoss1_pn3n3_zK5GclPE0cDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Numerator – net loss attributable to Harrow Health, Inc. common stockholders</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,950</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(237</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,733</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(13,144</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zwNEb8yf8t16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator - weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,736,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,379,943</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_pid_zdkBZ4eZHDk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Investment in Eton Pharmaceuticals, Inc. During the three and six months ended June 30, 2021, the Company sold 1,518,000 shares of its Eton Pharmaceuticals, Inc. (“Eton”) common stock through an underwritten public offering at a public offering price of $7.00 per share (the “Eton Stock Sale”). The gross proceeds to the Company from the Eton Stock Sale were $10,626, before deducting underwriting discounts and commissions and other offering expenses payable by the Company of $799. During the three and six months ended June 30, 2021, the Company recorded a realized loss of $1,406 related to the sale of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20210630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zUyC7pL9Uqae" title="Sale of stock. shares issued">1,518,000 shares of its Eton common stock. Following the Eton Stock Sale and as of June 30, 2021, the Company owns 1,982,000 shares of Eton common stock, which represents less than <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember__srt--RangeAxis__srt--MaximumMember_ziTcoDvJqA07" title="Equity method investment, ownership percentage">10% of the equity interests of Eton. At June 30, 2021, the fair market value of Eton’s common stock was $6.16 per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $(2,178) and $(5,013) and $4,725 and $(6,125) during the three and six months ended June 30, 2021 and 2020, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of June 30, 2021, the fair market value of the Company’s investment in Eton was $12,209. As part of the Eton Stock Sale, the Company also agreed, for a period of 180 days, not to conduct any further sales of shares of its common stock of Eton or otherwise dispose of, directly or indirectly, any common stock of Eton (or any securities convertible into, or exercisable or exchangeable for, the common stock of Eton). Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately 44% of the equity interests as of June 30, 2021) of Melt and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. During the three months ended June 30, 2021 and 2020, the Company recorded equity in the net losses of Melt of $477 and $690, and $947 and $1,236 during the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021 and December 31, 2020, the Company’s investment in Melt was $1,594 and $2,506, respectively, which includes $885 and $851, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”). See Note 4 for more information and related party disclosure regarding Melt. Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately 20% of the equity interests following the close of a round of financing completed by Surface at various dates from May 2021 to July 2021) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net losses of Surface of $465 and $599 during the three months and $1,314 and $938 during the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021 and December 31, 2020, the Company’s investment in Surface was $0 and $1,314, respectively. See Notes 5 for more information and related party disclosure regarding Surface. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Software costs during the application development stage used to meet the Company’s internal needs are generally capitalized. Computer software and hardware and furniture and equipment are depreciated over three to five years. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. This guidance became effective for the Company on January 1, 2021 on a prospective basis. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

Risks, Uncertainties and Liquidity The Company is subject to certain regulatory standards, approvals, guidelines and inspections which could impact the Company’s ability to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as a result of regulatory guidelines or inspections, this may have a material impact on the Company’s financial condition, liquidity and results of operations.

Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information of our operating segments. The Company has identified two operating segments as reportable segments. See Note 16 for more information regarding the Company’s reportable segments.

Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interest that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">each component of other income or loss.</td></tr> </table>

Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well

Basic and Diluted Net Loss per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period. Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common equivalent shares (using the treasury stock or “if converted” method) from stock options, unvested restricted stock units (“RSUs”) and warrants were 4,121,398 and 5,414,504 at June 30, 2021 and 2020, respectively. For the three and six months ended June 30, 2021 and 2020, the common equivalent shares are excluded in the calculation of diluted net loss per share because the effect is anti-dilutive. Included in the basic and diluted net loss per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at June 30, 2021 and 2020 was 235,973 and 251,746, respectively. The following table shows the computation of basic and diluted net loss per share of common stock for the three and six months ended June 30, 2021 and 2020: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49F_20210401__20210630_zITFYKgXI2ji" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200401__20200630_zbnXl9ZnZq5l" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49C_20210101__20210630_zwYuglV9O3Ql" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200101__20200630_zTu58KMR8hA5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Six Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 12pt">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr id="xdx_40A_ecustom--NetIncomeLoss1_pn3n3_zK5GclPE0cDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Numerator – net loss attributable to Harrow Health, Inc. common stockholders</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,950</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(237</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,733</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(13,144</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zwNEb8yf8t16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator - weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,736,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,379,943</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_pid_zdkBZ4eZHDk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

4121398 5414504 235973 251746

The following table shows the computation of basic and diluted net loss per share of common stock for the three and six months ended June 30, 2021 and 2020: SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49F_20210401__20210630_zITFYKgXI2ji" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200401__20200630_zbnXl9ZnZq5l" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49C_20210101__20210630_zwYuglV9O3Ql" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49A_20200101__20200630_zTu58KMR8hA5" style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">For the Six Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 12pt">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr id="xdx_40A_ecustom--NetIncomeLoss1_pn3n3_zK5GclPE0cDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Numerator – net loss attributable to Harrow Health, Inc. common stockholders</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,950</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(237</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(2,733</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(13,144</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zwNEb8yf8t16" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Denominator - weighted average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,736,970</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,893,629</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,379,943</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,867,478</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDiluted_pid_zdkBZ4eZHDk4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.11</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.51</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-2950000 -237000 -2733000 -13144000

26736970

25893629

26379943

25867478

-0.11

-0.01

-0.10

-0.51

Investment in Eton Pharmaceuticals, Inc. During the three and six months ended June 30, 2021, the Company sold 1,518,000 shares of its Eton Pharmaceuticals, Inc. (“Eton”) common stock through an underwritten public offering at a public offering price of $7.00 per share (the “Eton Stock Sale”). The gross proceeds to the Company from the Eton Stock Sale were $10,626, before deducting underwriting discounts and commissions and other offering expenses payable by the Company of $799. During the three and six months ended June 30, 2021, the Company recorded a realized loss of $1,406 related to the sale of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20210630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zUyC7pL9Uqae" title="Sale of stock. shares issued">1,518,000 shares of its Eton common stock. Following the Eton Stock Sale and as of June 30, 2021, the Company owns 1,982,000 shares of Eton common stock, which represents less than <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210630__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember__srt--RangeAxis__srt--MaximumMember_ziTcoDvJqA07" title="Equity method investment, ownership percentage">10% of the equity interests of Eton. At June 30, 2021, the fair market value of Eton’s common stock was $6.16 per share. In accordance with the Accounting Standards Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, the Company recorded an unrealized investment gain (loss) from its Eton common stock position of $(2,178) and $(5,013) and $4,725 and $(6,125) during the three and six months ended June 30, 2021 and 2020, respectively, related to the change in fair market value of its investment in Eton during the measurement period. As of June 30, 2021, the fair market value of the Company’s investment in Eton was $12,209. As part of the Eton Stock Sale, the Company also agreed, for a period of 180 days, not to conduct any further sales of shares of its common stock of Eton or otherwise dispose of, directly or indirectly, any common stock of Eton (or any securities convertible into, or exercisable or exchangeable for, the common stock of Eton).

1518000

7.00

10626000

799000

1406000

1518000

1982000

0.10

6.16

-2178000

-5013000

4725000

-6125000

12209000

Investment in Melt Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately 44% of the equity interests as of June 30, 2021) of Melt and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. During the three months ended June 30, 2021 and 2020, the Company recorded equity in the net losses of Melt of $477 and $690, and $947 and $1,236 during the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021 and December 31, 2020, the Company’s investment in Melt was $1,594 and $2,506, respectively, which includes $885 and $851, respectively, due from Melt for reimbursable expenses and amounts due under a Management Services Agreement between the Company and Melt (the “Melt MSA”). See Note 4 for more information and related party disclosure regarding Melt.

3500000

0.44

477000

690000

947000

1236000

1594000

2506000

885000

851000

Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately 20% of the equity interests following the close of a round of financing completed by Surface at various dates from May 2021 to July 2021) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net losses of Surface of $465 and $599 during the three months and $1,314 and $938 during the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021 and December 31, 2020, the Company’s investment in Surface was $0 and $1,314, respectively. See Notes 5 for more information and related party disclosure regarding Surface.

3500000

0.20

465000

599000

1314000

938000

1314000

Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Software costs during the application development stage used to meet the Company’s internal needs are generally capitalized. Computer software and hardware and furniture and equipment are depreciated over three to five years.

three to five years

Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. This guidance became effective for the Company on January 1, 2021 on a prospective basis. Adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers. The Company has three primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services, (2) revenue recognized from a commission agreement with a third party and (3) revenue recognized from intellectual property license and asset purchase agreements. Product Revenues from Pharmacy Services The Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services division includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principles of ASC 606, we have identified the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases the product the customer is wishing to receive. If we are unable to meet the performance obligation, the customer is notified. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determine the transaction price: the transaction price is based on the product being sold to the customer and any related customer discounts. These amounts are pre-determined and built into our order management software. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocate the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being ordered is allocated according to the pre-determined amounts.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognize revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility, the performance obligation has been met. </td></tr> </table> The following revenue recognition policy has been established for the pharmacy services division: Revenues generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required. Commission Revenues During the year ended December 31, 2020, the Company entered into an agreement whereby it is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue. Intellectual Property License Revenues As of June 30, 2021, we are party to four intellectual property licenses and asset purchase agreements in which we have agreed to grant a license and which provide a customer with the right to access the Company’s intellectual property. License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point in time at which the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source for the three and six months ended June 30, 2021 and 2020, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zUU2Rjm3ll5e" style="width: 10%; text-align: right" title="Total Revenues">17,297</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_ztUfAjvel2ck" style="width: 10%; text-align: right" title="Total Revenues">8,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" style="width: 10%; text-align: right" title="Total Revenues">32,245</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" style="width: 10%; text-align: right" title="Total Revenues">19,859</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-weight: bold; text-align: left">Commission revenues</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--CommissionsMember_zAaOL9TSHRQ3" style="text-align: right" title="Total Revenues">827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pdn3_c20200401__20200630__srt--ProductOrServiceAxis__custom--CommissionsMember_zdy5u4GdnCA9" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">1,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CommissionsMember_pdn3" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">License revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zOYUlrbtqyte" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zqWfEQt7g6G8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630_z8fO3FDS6xV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">18,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630_zPQRwEIJ4Oj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">8,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">33,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">19,877</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred revenue and customer deposits at June 30, 2021 and December 31, 2020, were $56 and $66, respectively. All deferred revenue and customer deposit amounts at December 31, 2020 were recognized as revenue during the six months ended June 30, 2021.

Revenue disaggregated by revenue source for the three and six months ended June 30, 2021 and 2020, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zUU2Rjm3ll5e" style="width: 10%; text-align: right" title="Total Revenues">17,297</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_ztUfAjvel2ck" style="width: 10%; text-align: right" title="Total Revenues">8,049</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" style="width: 10%; text-align: right" title="Total Revenues">32,245</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" style="width: 10%; text-align: right" title="Total Revenues">19,859</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-weight: bold; text-align: left">Commission revenues</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__custom--CommissionsMember_zAaOL9TSHRQ3" style="text-align: right" title="Total Revenues">827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pdn3_c20200401__20200630__srt--ProductOrServiceAxis__custom--CommissionsMember_zdy5u4GdnCA9" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">1,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CommissionsMember_pdn3" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">License revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zOYUlrbtqyte" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">10</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zqWfEQt7g6G8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">18</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20210401__20210630_z8fO3FDS6xV3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">18,134</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630_zPQRwEIJ4Oj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">8,060</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">33,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">19,877</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

17297000

8049000

32245000

19859000

827000

1312000

10000

11000

20000

18000

18134000

8060000

33577000

19877000

56000

66000

<p id="xdx_80C_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zPirinPBP7C1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4. INVESTMENT IN MELT PHARMACEUTICALS, INC. RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single-digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement. See also Note 2, under the subheading Investment in Melt Pharmaceuticals, Inc. In February 2019, the Company and Melt entered into the Melt MSA, whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt is required to pay the Company a monthly amount of $<span id="xdx_90F_eus-gaap--AdministrativeFeesExpense_c20190201__20190228__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Administrative fees expense">10. As of June 30, 2021 and December 31, 2020, the Company was due $<span id="xdx_90B_eus-gaap--DueFromRelatedParties_c20210630__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Due from related parties">885 and $<span id="xdx_906_eus-gaap--DueFromRelatedParties_c20201231__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Due from related parties">851, respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did not make any payments to the Company during the three and six months ended June 30, 2021. The Company’s Chief Executive Officer, Mark L. Baum is a member of the Melt board of directors, and several employees of the Company (including Mr. Baum and the Company’s Chief Financial Officer, Andrew R. Boll) entered into consulting agreements and provide consulting services to Melt. The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">2,177</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">2,574</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,177</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">At June 30,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">At December 31,</td><td style="text-align: center"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsCurrent_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 22%; text-align: right" title="Current assets">2,947</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zx0pou8vDrQ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zCArlLx8yskd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z5srEgez8hKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Current assets"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Current assets"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Liabilities_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,778</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ (deficit) equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzWIkAobLJAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' (deficit) equity">(759</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2pa0a6iRJyi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' (deficit) equity">1,180</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDwWWgJbMDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">1,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

10000

885000

851000

The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">2,177</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">2,574</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,177</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(2,574</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

2177000

2574000

-2177000

-2574000

The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">At June 30,</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">At December 31,</td><td style="text-align: center"> </td></tr> <tr> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsCurrent_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 22%; text-align: right" title="Current assets">2,947</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zx0pou8vDrQ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsNoncurrent_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zCArlLx8yskd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z5srEgez8hKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Current assets"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Current assets"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--Liabilities_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,778</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ (deficit) equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--StockholdersEquity_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zzWIkAobLJAh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' (deficit) equity">(759</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--StockholdersEquity_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z2pa0a6iRJyi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' (deficit) equity">1,180</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pn3n3_c20210630__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zHDwWWgJbMDg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">1,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

927000

2947000

98000

11000

1025000

2958000

1784000

1778000

-759000

1180000

1025000

2958000

NOTE 5. INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS The Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights associated with Surface’s drug candidates (collectively, the “Surface Products”). Surface is required to make mid-single-digit royalty payments to the Company on net sales of the Surface Products while any patent rights remain outstanding. As of June 30, 2021, the Company owned 3,500,000 shares of Surface common stock. A Company director, Richard L. Lindstrom, and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of net sales of certain Surface products while certain patent rights remain outstanding. Dr. Lindstrom is also a minority owner of Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. Several employees and a director of the Company (including Mr. Baum and Dr. Lindstrom) entered into consulting agreements and provide consulting services to Surface. The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">4,712</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">3,127</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(4,712</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,127</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr> <td> </td><td> </td> <td colspan="2" style="text-align: center">At June 30,</td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center">At December 31,</td><td> </td></tr> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsCurrent_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">25,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">9,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsNoncurrent_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--Assets_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">25,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">9,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Liabilities_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,666</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockholdersEquity_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' equity">24,058</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' equity">7,453</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesAndStockholdersEquity_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">25,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">9,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3500000

The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">For the Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pdn3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="width: 56%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">4,712</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations">3,127</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_c20210101__20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(4,712</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLoss_c20200101__20200630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,127</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

4712000

3127000

-4712000

-3127000

The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr> <td> </td><td> </td> <td colspan="2" style="text-align: center">At June 30,</td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center">At December 31,</td><td> </td></tr> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsCurrent_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">25,786</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets">9,074</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsNoncurrent_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--Assets_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">25,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">9,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Liabilities_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,666</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--StockholdersEquity_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' equity">24,058</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders' equity">7,453</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--LiabilitiesAndStockholdersEquity_c20210630__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">25,829</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">9,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

25786000

9074000

43000

45000

25829000

9119000

1771000

1666000

24058000

7453000

25829000

9119000

NOTE 6. RESTRICTED CASH The restricted cash at June 30, 2021 and December 31, 2020 consisted of funds held in a money market account. At June 30, 2021 and December 31, 2020, the restricted cash was recorded at amortized cost, which approximates fair value. At June 30, 2021 and December 31, 2020, the funds held in a money market account of $200 were classified as a current asset. The money market account funds are required as collateral as additional security for the Company’s New Jersey facility lease.

200000

NOTE 7. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of June 30, 2021 and December 31, 2020 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210630_z5zCYLiJmk92" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20201231_zyQjyJs9T0rc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzOAz_zUX0PBCHoByi" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,501</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzOAz_zZ7G2LSl4mG6" style="background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzOAz_zKLXCD2hCaMd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,896</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzOAz_zLaRy40uZit7" style="background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,962</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of June 30, 2021 and December 31, 2020 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210630_z5zCYLiJmk92" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20201231_zyQjyJs9T0rc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzOAz_zUX0PBCHoByi" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,501</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzOAz_zZ7G2LSl4mG6" style="background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzOAz_zKLXCD2hCaMd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,896</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,444</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzOAz_zLaRy40uZit7" style="background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,962</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1990000

2501000

17000

1896000

1444000

3903000

3962000

NOTE 8. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at June 30, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210630_zJDLvuamJVu4" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20201231_zjVfyh8CSYIh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAz12j_zrqFG2XHfM5d" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAz12j_zcYGZLAnkVFi" style="background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">607</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAz12j_zKFJ5ug9orxd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iTI_pn3n3_mtPEAOAz12j_zt0nwO3NQPC4" style="background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Prepaid expenses and other current assets at June 30, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210630_zJDLvuamJVu4" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20201231_zjVfyh8CSYIh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAz12j_zrqFG2XHfM5d" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">160</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAz12j_zcYGZLAnkVFi" style="background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">607</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAz12j_zKFJ5ug9orxd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">190</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_iTI_pn3n3_mtPEAOAz12j_zt0nwO3NQPC4" style="background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">801</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">751</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

120000

160000

607000

401000

74000

190000

801000 751000

NOTE 9. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at June 30, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20210630_z9Ho68bHP1xb" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zbHY0eDQgVtl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzEF6_zln2cdfZB7w9" style="background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,427</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--SoftwareCostsInDevelopmentGross_iI_maCzEF6_zh8xjiq0ePol" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Internal use software costs in development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">803</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">337</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_maCzEF6_zMAgw5sLq2pe" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MachineryAndEquipmentGross_iI_maCzEF6_zxiIWZpnznpd" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,426</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseholdImprovementsGross_iI_maCzEF6_zW5qRc08hfp" style="background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,735</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtCzEF6_maCzW0r_z0HfYHaquW74" style="background-color: rgb(204,238,255)"> <td>Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,271</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzW0r_z8hUFSFcnNsg" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,694</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtCzW0r_zERWFwBE0nLh" style="background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three and six months ended June 30, 2021, depreciation and amortization related to the property, plant and equipment was $412 and $876, respectively. For the three and six months ended June 30, 2020, depreciation and amortization related to the property, plant and equipment was $465 and $913, respectively.

Property, plant and equipment at June 30, 2021 and December 31, 2020, consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20210630_z9Ho68bHP1xb" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zbHY0eDQgVtl" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCzEF6_zln2cdfZB7w9" style="background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,427</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--SoftwareCostsInDevelopmentGross_iI_maCzEF6_zh8xjiq0ePol" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Internal use software costs in development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">803</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">337</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_maCzEF6_zMAgw5sLq2pe" style="background-color: White"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--MachineryAndEquipmentGross_iI_maCzEF6_zxiIWZpnznpd" style="background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,426</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LeaseholdImprovementsGross_iI_maCzEF6_zW5qRc08hfp" style="background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,735</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iTI_mtCzEF6_maCzW0r_z0HfYHaquW74" style="background-color: rgb(204,238,255)"> <td>Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,271</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzW0r_z8hUFSFcnNsg" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,694</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtCzW0r_zERWFwBE0nLh" style="background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,453</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1427000

1370000

803000 337000

441000

418000

4225000

3426000

5735000

5720000

12631000

11271000

7694000

6818000

4937000

4453000

412000

876000

465000

913000

NOTE 10. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at June 30, 2021 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization periods (in years)</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net carrying value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 35%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9UWpH9NOiod" title="Amortization periods (in years)">17-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zynZOZtYnOW8" title="Amortization periods (in years)">19 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Cost">540</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Accumulated amortization">(60</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pdn3" style="width: 9%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Net carrying value">480</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z4K0QlIjxfuh" title="Amortization periods (in years)">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeVAgjE8rdea" style="text-align: right" title="Net carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pdn3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net carrying value">358</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zBUAxHvXU0x2" title="Amortization periods (in years)">3-<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zU3HgXEnnEph" title="Amortization periods (in years)">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(520</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net carrying value">999</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zJNi7KSlcoP1" title="Amortization periods (in years)">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z5HruJ1QxMcf" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zmV3j7NJutvl" title="Amortization periods (in years)">3-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzMCwdFRRRdb" title="Amortization periods (in years)">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zFyx1R42si9e" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z7r9KxjfzZJe" title="Amortization periods (in years)">25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pdn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630_pdn3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210630_zm1z6T371bQf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,882</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization expense for intangible assets for the three and six months ended June 30, 2021 and 2020 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the Six Months Ended</td><td style="text-align: center"> </td></tr> <tr> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPZhcpUR5AY1" style="width: 12%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQg2Bhn8dhW5" style="width: 12%; text-align: right" title="Amortization of intangible assets">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">19</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zb7ESZKc94q6" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zzx9aaaVTMx4" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zCEFRGScCY99" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8ThD90E44z5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">68</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-size: 12pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630_zrfODSNCgFbj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630_z3mm1hATc4Xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Estimated future amortization expense for the Company’s intangible assets at June 30, 2021 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210630_zNPghuS69hE2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maCz3hx_zWFLbUHFMTO9" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">110</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maCz3hx_zJokRvFkmZcj" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maCz3hx_zJFbmm0hphqd" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maCz3hx_z5EsW6gqhndd" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maCz3hx_zvwzvA6mW0m5" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maCz3hx_zxBHphKdN7Li" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">729</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCz3hx_zChVww7IZ0Jd" style="background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The Company’s intangible assets at June 30, 2021 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization periods (in years)</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Cost</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated amortization</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net carrying value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 35%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 9%; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z9UWpH9NOiod" title="Amortization periods (in years)">17-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zynZOZtYnOW8" title="Amortization periods (in years)">19 </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Cost">540</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Accumulated amortization">(60</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pdn3" style="width: 9%; text-align: right" title="Impairment">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 9%; text-align: right" title="Net carrying value">480</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z4K0QlIjxfuh" title="Amortization periods (in years)">20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zeVAgjE8rdea" style="text-align: right" title="Net carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">358</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pdn3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net carrying value">358</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zBUAxHvXU0x2" title="Amortization periods (in years)">3-<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zU3HgXEnnEph" title="Amortization periods (in years)">15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(520</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net carrying value">999</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zJNi7KSlcoP1" title="Amortization periods (in years)">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z5HruJ1QxMcf" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zmV3j7NJutvl" title="Amortization periods (in years)">3-<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzMCwdFRRRdb" title="Amortization periods (in years)">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pdn3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zFyx1R42si9e" style="text-align: right" title="Net carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z7r9KxjfzZJe" title="Amortization periods (in years)">25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pdn3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsGross_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20210630_pdn3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20210630_zm1z6T371bQf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,882</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P17Y

P19Y

540000

-60000

480000

P20Y

50000

-6000

44000

Indefinite

358000

P3Y

P15Y

1519000

-520000

999000

P5Y

5000

-5000

P3Y

P4Y

50000

-50000

P25Y

8000

-7000

1000

2530000

-648000

1882000

Amortization expense for intangible assets for the three and six months ended June 30, 2021 and 2020 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the Six Months Ended</td><td style="text-align: center"> </td></tr> <tr> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPZhcpUR5AY1" style="width: 12%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQg2Bhn8dhW5" style="width: 12%; text-align: right" title="Amortization of intangible assets">8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">19</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zb7ESZKc94q6" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zzx9aaaVTMx4" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zCEFRGScCY99" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">33</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z8ThD90E44z5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">68</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="font-size: 12pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20210401__20210630_zrfODSNCgFbj" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200401__20200630_z3mm1hATc4Xf" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">43</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">79</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">88</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6000

8000

12000

19000

1000

33000

35000

66000

68000

39000

43000

79000

8000

Estimated future amortization expense for the Company’s intangible assets at June 30, 2021 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210630_zNPghuS69hE2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maCz3hx_zWFLbUHFMTO9" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">110</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maCz3hx_zJokRvFkmZcj" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maCz3hx_zJFbmm0hphqd" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maCz3hx_z5EsW6gqhndd" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maCz3hx_zvwzvA6mW0m5" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maCz3hx_zxBHphKdN7Li" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">729</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCz3hx_zChVww7IZ0Jd" style="background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

110000

188000

161000

148000

729000

1524000

NOTE 11. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210630_z8YZawkS7eDf" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20201231_zPkvS4Keyyl1" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maCzs7p_zJJRlCYwxcl6" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maCzs7p_zpc2SRj9GJsi" style="background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maCzs7p_z5souupoPjk6" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maCzs7p_z1oH7wO886D6" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for loan payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtCzs7p_zAILApDrhpSf" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,207</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_di_zeCdfyDOcQBe" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_zlub7L2yR4k4" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210630_z8YZawkS7eDf" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20201231_zPkvS4Keyyl1" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maCzs7p_zJJRlCYwxcl6" style="background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_maCzs7p_zpc2SRj9GJsi" style="background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maCzs7p_z5souupoPjk6" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,276</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">238</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maCzs7p_z1oH7wO886D6" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for loan payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtCzs7p_zAILApDrhpSf" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,207</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_di_zeCdfyDOcQBe" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,207</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,932</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_zlub7L2yR4k4" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3882000

3645000

49000

1276000

238000

800000

5207000

4732000

5207000

3932000

800000

NOTE 12. DEBT 8.625% Senior Notes Due 2026 In April 2021, the Company closed an offering of $50,000 aggregate principal amount of 8.625% senior notes due in April 2026 and in May 2021 issued an additional $<span id="xdx_904_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_pn3n3_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zz8tIdJFZMF7" title="Additional notes issued">5,000 of such notes pursuant to the full exercise of the underwriters’ option to purchase additional notes (collectively, the “April Notes”). The April Notes were sold to investors at a par value of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zXx79GYGyri8" title="Share price">25.00 per April Note and the offering resulted in net proceeds to the Company of approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zZFPqkzsiPt" title="Proceeds from issuance of debt">51,909 after deducting underwriting discounts and commissions and expenses of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_c20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zdonuSM9Kqlc" title="Debt issuance costs and discounts">3,091. In June 2021, in a further issuance of the April Notes, the Company sold an additional $<span id="xdx_90C_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_pn3n3_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zXfQRMJYx4jj" title="Additional notes issued">20,000 aggregate principal amount of such notes (the “June Notes,” and together with the April Notes, the “Notes”), at a price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z96DD3Nb0W3c">25.75 per June Note, with interest of $<span id="xdx_906_eus-gaap--InterestExpenseDebt_pn3n3_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zaEW8Y818hN6" title="Interest expense, debt">278 on the June Notes being accrued from April 20, 2021 as of the date of issuance. The June offering resulted in net proceeds to the Company of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_pn3n3_c20210601__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zvGWaWJ0RY6k" title="Proceeds from issuance of debt">19,164 after deducting underwriting discounts and commissions and expenses of $<span id="xdx_905_eus-gaap--DeferredFinanceCostsNet_iI_pn3n3_c20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzdEqeGctU16" title="Debt issuance costs">1,158 and a premium on note issuance of $322. The June Notes are treated as a single series with the April Notes under the indenture governing the April Notes, dated as of April 20, 2021, and have the same terms as the April Notes (other than the initial offering price and issue date). The Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of our other existing and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in right of payment to all of the Company’s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the Company’s subsidiaries, including trade payables. The Notes bear interest at a rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zj1IkpJqZFL3" title="Debt instrument, interest rate">8.625% per annum. Interest on the Notes is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The Notes will mature on April 30, 2026. The issuance costs were recorded as a debt discount and are being amortized as interest expense, net of the amortization of the premium on note issuance, over the term of the Notes using the effective interest rate method. Prior to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus a make-whole amount, if any, plus accrued and unpaid interest to, but excluding, the date of redemption. The Company may redeem the Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity, at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. Interest expense related to the Notes totaled $1,466 for the three and six months ended June 30, 2021, and included amortization of debt issuance costs and discount of $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20210401__20210430__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_zlPIiuhx8ny7" title="Amortization of debt issuance costs and discount"><span id="xdx_90A_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20210101__20210630__us-gaap--LongtermDebtTypeAxis__custom--Sec8.625SeniorNotesDue2026Member_z8SQASw99w6b" title="Amortization of debt issuance costs and discount">192 for the three and six months ended June 30, 2021. SWK Senior Note – Paid in April 2021 In July 2017, the Company and several of its wholly owned subsidiaries entered into a term loan and security agreement in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_pn3n3" title="Debt principal amount">16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (collectively, “SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term; however, such term could be reduced to four years if certain revenue requirements were not achieved. The SWK Loan was secured by substantially all of the Company’s assets, including its intellectual property rights. The SWK Loan was subsequently amended in May 2019 and again in April 2020. The SWK Loan bore an interest rate equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zQLhsbYTOXH6" title="Debt instrument interest rate">2.00%), plus an applicable margin of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__us-gaap--VariableRateAxis__us-gaap--BaseRateMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zQizARPLxd99" title="Debt instrument interest rate">10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provided SWK evidence that the <span id="xdx_90A_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20170701__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember" title="Debt instrument interest rate description">Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company had achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12 month period, adding-back (i) actual litigation expenses for the immediately preceding 12 month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by 4. A summary of the material changes contained in the amendment entered into with SWK in April 2020 was as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SWK agreed to make available to the Company, and the Company drew down on, an additional principal amount of $<span id="xdx_903_ecustom--DebtInstrumentAdditionalPrincipalAmount_iI_c20210430__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zPJRUzjciaih" title="Debt instrument, additional principal amount">1,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Second Amendment; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The interest payment of $<span id="xdx_904_eus-gaap--PaidInKindInterest_c20210401__20210430__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zJ6flAL9x6vf" title="Interest paid-in-kind">358 due May 14, 2020 was paid in-kind by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.</td></tr> </table> Interest expense related to the SWK Loan Agreement, as amended, amounted to $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_pn3n3_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zZi2RgSgWk3b">138 and $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_pn3n3_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zrmOjNg5zbSd">647 for the three and six months ended June 30, 2021, respectively, and $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pn3n3_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zuyNQvrcWbD2">505 and $<span id="xdx_909_eus-gaap--InterestExpenseDebt_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zgBb5XGZio55">1,065 for the three and six months ended June 30, 2020, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zXFYl3Uec8R2" title="Amortization of debt issuance costs and discount">0 and $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zTyi0xsti596" title="Amortization of debt issuance costs and discount">96 for the three and six months ended June 30, 2021, respectively, and $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zCTYwxOND6u" title="Amortization of debt issuance costs and discount">83 and $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pn3n3_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zufZM4gQMZQc" title="Amortization of debt issuance costs and discount">243 for the three and six months ended June 30, 2020, respectively. In April 2021, the Company paid $15,540 related to all outstanding obligations to SWK under the SWK Loan, including outstanding principal, accrued interest, accrued exit fee and related expenses and recorded a loss from early extinguishment of $<span id="xdx_907_eus-gaap--ExtinguishmentOfDebtAmount_pn3n3_c20210401__20210630__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--RegulatoryAssetAxis__us-gaap--DeferredLossOnEarlyExtinguishmentOfDebtMember_zIvH7oZMtz8d" title="Extinguishment of debt">756 related to the SWK Loan during the three and six months ended June 30, 2021. Paycheck Protection Program Loan – Forgiven in March 2021 In April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender, for a loan (the “PPP Loan”) in the principal amount of $1,967 and received cash proceeds of the same amount, pursuant to the Paycheck Protection Program (the “PPP”) under the Federal Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration (the “SBA”). On March 30, 2021, the Company received a notice of forgiveness of the full balance of the PPP Loan, including all accrued interest, in accordance with the terms and conditions of the CARES Act. Related to the forgiveness, the Company recorded a gain on the forgiveness of the PPP Loan for the loan balance of $1,967 in the accompanying condensed consolidated statement of operations for the six months ended June 30, 2021. At June 30, 2021, future minimum payments under the Company’s debt were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210630_zkoWVVPUMNpb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzCfL_zuy3nFECidKd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,308</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzCfL_zPLBMwLAdrn7" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzCfL_z4Aj347IvUkh" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzCfL_zRECSja7os6i" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,580</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzCfL_z3quj8oLkkKg" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maCzCfL_zIIJbSn5AdOc" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_mtCzCfL_zycegTQiD5M4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iNI_di_zEkgEvIrg2Xa" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,732</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_ziOtLRJ4X62l" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_zzsgCaDpEsT8" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,735</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--LongTermNotesPayable1_iI_zN9xEBu947al" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

50000000

5000000

25.00

51909000

3091000

20000000

25.75

278000

19164000

1158000

322000

0.08625

redemption price equal to 100% of the principal amount

1466000

192000

16000000

0.0200

0.1000

Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company had achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%.

1000000

358000

138000

647000

505000

1065000

96000

83000

243000

15540000

756000

1967000

At June 30, 2021, future minimum payments under the Company’s debt were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210630_zkoWVVPUMNpb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_maCzCfL_zuy3nFECidKd" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">3,308</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maCzCfL_zPLBMwLAdrn7" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maCzCfL_z4Aj347IvUkh" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maCzCfL_zRECSja7os6i" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,580</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maCzCfL_z3quj8oLkkKg" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_maCzCfL_zIIJbSn5AdOc" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_mtCzCfL_zycegTQiD5M4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,732</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iNI_di_zEkgEvIrg2Xa" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,732</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_ziOtLRJ4X62l" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_zzsgCaDpEsT8" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized discount, net of premium</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,735</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_ecustom--LongTermNotesPayable1_iI_zN9xEBu947al" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Notes payable, net of unamortized discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">71,265</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3308000

6562000

6580000

6562000

77158000

106732000

31732000

75000000

-3735000 71265000

NOTE 13. LEASES The Company leases office and laboratory space under non-cancelable operating leases listed below. These lease agreements have remaining terms between one to four years and contain various clauses for renewal at the Company’s option. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 10,200 square feet of office space in San Diego, California that expires in December 2021;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 26,400 square feet of lab, warehouse and office space in Ledgewood, New Jersey that expires in July 2026, with an option to extend the term for two additional five-year periods. This includes an amendment that was made effective July 2020 that extended the term of the original lease and added <span id="xdx_909_eus-gaap--AreaOfLand_iI_pid_uSqft_c20210630__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--LeaseContractualTermAxis__custom--AdditionalSquareFootageOfLeaseMember_zWlHXj2rmOEe" title="Operating lease space">1,400 of additional square footage to the lease and another amendment entered into in May 2021 that extended the <span id="xdx_905_eus-gaap--LesseeOperatingLeaseDescription_c20210601__20210630__srt--StatementGeographicalAxis__custom--LedgewoodMember__us-gaap--LeaseContractualTermAxis__custom--AdditionalSquareFootageOfLeaseMember_zWBFlZt97iQ3">term of the lease to July 2027; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 5,500 square feet of office space in Nashville, Tennessee that expires in December 2024, with an option to extend the term for two additional five-year periods.</td></tr> </table> In May 2021, the Company amended its New Jersey lease to include the addition of 8,926 square feet of space (the “May Lease Amendment”), which will expire in July 2027. The Company expects to take possession of this additional space in September 2021, which will trigger the commencement of the May Lease Amendment. Since the commencement date of the May Lease Amendment is expected to occur after June 30, 2021, right-of-use assets and operating lease liabilities associated with the May Lease Amendment are not included in the Company’s condensed consolidated balance sheets as of June 30, 2021. At June 30, 2021, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 6.32% and 14.08 years, respectively. During the three and six months ended June 30, 2021, cash paid for amounts included for the operating lease liabilities was $251 and $502, respectively, and the Company recorded operating lease expense of $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_pn3n3_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zcWXh2tSpDk" title="Operating lease expense">241 and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pn3n3_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_znAg6pi38GZf" title="Operating lease expense">502 included in selling, general and administrative expenses, respectively. Future lease payments under operating leases as of June 30, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210630_zS34Z8TxRn9j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzKTl_zMss5pdZttX7" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">502</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzKTl_zYiMrWW0FtZ8" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maCzKTl_zNWHQttGdPc4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maCzKTl_zvkGN8JH1tNd" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">617</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maCzKTl_zFOIOdIwJsN3" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">433</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maCzKTl_znbxhuP3kya3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtCzKTl_zmI8LA4z6ph" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zsgXxqwNwjQ3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zOHMC3xkH8Bd" style="background-color: rgb(204,238,255)"> <td style="text-align: left"> Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,180</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zvzB8opNhIu8" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsf2OkFLfGQ2" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company also has a finance lease that is included in its lease accounting but is not considered significant. Future lease payments under the non-cancelable finance lease as of June 30, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210630_zXYzYPYEiXNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzVLe_zbVWOsS0CxRb" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzVLe_zZVjNuqJAs94" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maCzVLe_zK5nidEs7Vi4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maCzVLe_z3BzRcrOXGi2" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzVLe_zH6lSGUFwId7" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI7e0ThMhYdb" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiability_iI_z2QqZlEu8oak" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zuow2Lu8wys3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zHIQJZM8hWKc" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At June 30, 2021, the weighted average incremental borrowing rate and the weighted average remaining lease term for the finance lease held by the Company were 6.36% and 2.58 years, respectively. For the three and six months ended June 30, 2021, depreciation expense related to the equipment held under the finance lease obligation was $<span id="xdx_901_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_pn3n3_c20210401__20210630_z0tBkx4Zrech" title="Operating leases, income statement, depreciation expense on property subject to or held-for-lease">2 and $<span id="xdx_906_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_pn3n3_c20210101__20210630_ztDnFL54P49" title="Operating leases, income statement, depreciation expense on property subject to or held-for-lease">4, respectively. For the three and six months ended June 30, 2021, cash paid and expense recognized for interest expense related to the finance lease obligation was $0 and $1, respectively.

10200

December 2021

26400

July 2026

term for two additional five-year periods

1400

term of the lease to July 2027

5500

December 2024

term for two additional five-year periods

8926

July 2027 0.0632

P14Y29D

251000

502000

241000

502000

Future lease payments under operating leases as of June 30, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20210630_zS34Z8TxRn9j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzKTl_zMss5pdZttX7" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">502</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzKTl_zYiMrWW0FtZ8" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maCzKTl_zNWHQttGdPc4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maCzKTl_zvkGN8JH1tNd" style="background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">617</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maCzKTl_zFOIOdIwJsN3" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">433</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maCzKTl_znbxhuP3kya3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,146</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtCzKTl_zmI8LA4z6ph" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,883</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zsgXxqwNwjQ3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zOHMC3xkH8Bd" style="background-color: rgb(204,238,255)"> <td style="text-align: left"> Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,180</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_zvzB8opNhIu8" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(485</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zsf2OkFLfGQ2" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

502000

585000

600000

617000

433000

5146000

7883000

2703000

5180000

485000

4695000

The Company also has a finance lease that is included in its lease accounting but is not considered significant. Future lease payments under the non-cancelable finance lease as of June 30, 2021 were as follows: SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td style="text-align: left; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210630_zXYzYPYEiXNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maCzVLe_zbVWOsS0CxRb" style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 78%">Remainder of 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maCzVLe_zZVjNuqJAs94" style="background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_maCzVLe_zK5nidEs7Vi4" style="background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_maCzVLe_z3BzRcrOXGi2" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_mtCzVLe_zH6lSGUFwId7" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_zI7e0ThMhYdb" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--FinanceLeaseLiability_iI_z2QqZlEu8oak" style="background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_zuow2Lu8wys3" style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_zHIQJZM8hWKc" style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5000

9000

1000

24000

2000

22000

8000

14000

0.0636

P2Y6M29D

2000

4000

1000

NOTE 14. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Preferred Stock At June 30, 2021 and 2020, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding. Series B Cumulative Preferred Stock – Redeemed In May 2021, the Company sold 440,000 shares of the Company’s Series B Cumulative Preferred Stock, par value $0.001 per share and liquidation preference of $25.00 per share (the “Series B Preferred Stock”), for a net purchase price of approximately $10,655. The Series B Preferred Stock was not convertible into our common stock, had no voting rights, except as required by Delaware law, and was redeemable by the Company at any time. Holders of Series B Preferred Stock were entitled to cumulative cash dividends at the rate of 9.50% of the $25.00 liquidation preference per year; provided, however, that for each thirty (30) day period following May 5, 2021, the dividend rate increased at various rates, except as otherwise limited by applicable law. Dividends were payable quarterly in arrears, on or about the 15th of January, April, July and October, beginning on or about July 15, 2021. In June 2021, the Company redeemed all of the outstanding shares of the Company’s Series B Preferred Stock, par value $0.001 per share. The redemption price for the 440,000 shares of Series B Preferred Stock outstanding was equal to $25.00 per share, plus accrued and unpaid dividends, which in aggregate totaled $<span id="xdx_901_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockRedeemedMember_znf3IvPddhFg" title="Accrued and unpaid dividends">11,127. During the three and six months ended June 30, 2021, the Company recorded preferred stock cash dividends and deemed dividends equal to $<span id="xdx_906_eus-gaap--DividendsPreferredStockCash_pn3n3_c20210101__20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockRedeemedMember_za9iDNUIxUg7" title="Preferred stock, cash dividends"><span id="xdx_906_eus-gaap--DividendsPreferredStockCash_pn3n3_c20210401__20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesBCumulativePreferredStockRedeemedMember_z2WXah82Cazi" title="Preferred stock, cash dividends">472. Common Stock During the six months ended June 30, 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXBYoImfEXrl" title="Number of shares isssued">311,369 shares of its common stock upon the cashless exercise of warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziWLs7WpUw7i" title="Warrants to purchase">406,539 shares of common stock with exercise prices between $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zO1B10aqMeT7" title="Warrants exercise price">1.79 and $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z8zu7RNNpi59">3.75 per share. During the six months ended June 30, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zBJxZv0DOW75">16,613 shares of its common stock upon the exercise of options to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zJjIUkio76lb" title="Number of securities called by warrants">16,613 shares of common stock with exercise prices between $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MinimumMember_zkwYMqJ2jvqd">1.70 and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__us-gaap--OptionMember__srt--RangeAxis__srt--MaximumMember_zrpcHJLCA09f">4.29 per share and received net proceeds of $48. During the six months ended June 30, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwzA4FmVbnb5" title="Number of shares isssued">715,871 shares of its common stock to Mark L. Baum, its CEO, related to the vesting of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKsWTsbsSvd8" title="Shares issued of restricted common stock, shares">1,050,000 performance-based restricted stock units. The Company withheld issuance of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNtzdrmljWki" title="Number of stock withheld for payroll tax purposes">334,129 shares of common stock valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT6LjwHlFMq3" title="Value of stock withheld for payroll tax purposes">2,760 for payroll tax purposes. During the six months ended June 30, 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9CKQMBP7Wfh" title="Number of shares isssued">100,168 shares of common stock to Andrew R. Boll, its CFO, related to the vesting of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKM2fvjQYL3h" title="Shares issued of restricted common stock, shares">157,500 performance-based restricted stock units. The Company withheld issuance of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCm6Eth3560l" title="Number of stock withheld for payroll tax purposes">57,332 shares of common stock to Mr. Boll for payroll tax purposes valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmY6f9w2PLY2" title="Value of stock withheld for payroll tax purposes">468. During the six months ended June 30, 2021, <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGXih0cK0cMf" title="Shares vested during period">35,510 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns. Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan which was subsequently amended on June 3, 2021 (as amended, the “2017 Plan” together with the 2007 Plan, the “Plans”). As of June 30, 2021, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zcMXYAfj1KWg" title="Maximum number of common stock issuance under the plan">6,000,000 shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210630__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_zW2EKaZhk4Q6" title="Shares available for future issuances">3,967,251 shares available for future issuances under the 2017 Plan at June 30, 2021. Stock Options A summary of stock option activity under the Plans for the six months ended June 30, 2021 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="vertical-align: bottom; text-align: center"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of Shares</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 36%">Options outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjBWYvDgc013" style="width: 12%; text-align: right" title="Number of shares, Outstanding, Beginning balance">3,030,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zEaNjY1v33jc" style="width: 12%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zcz0bwciuise" style="text-align: right" title="Number of shares, Options granted">67,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zoYmQMgrLvdk" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkyUeNqWgCaf" style="text-align: right" title="Number of shares, Options exercised">(16,613</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFr8WgubsPBl" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">2.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options cancelled/forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpV2X8KrI1P" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(29,945</td><td style="text-align: left">)</td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGqRUSzsG6Ff" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">5.32</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Options outstanding - June 30, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvafLl6U5wp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,050,475</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgaCP7cCwt8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.50</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zf7hzw3Qabod" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.28</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">11,555</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z77ESRmA9e27" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">2,333,132</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zstIei30cAEg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">5.01</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRywPgAyg7Ud" title="Weighted Avg. Remaining Contractual Life, Options exercisable">4.85</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">9,985</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Options vested and expected to vest</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGMFGMhDT3x" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,978,866</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8SRY2aULnd6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.46</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPCOzp1DNVQl" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.25</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">11,399</td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on June 30, 2021, based on the closing price of the Company’s common stock of $9.29 on that date. During the six months ended June 30, 2021, the Company granted stock options to certain employees and a consultant. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zzHRDF6Bchg7" title="Share-based compensation, contractual term">10 years. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zzHvaqWv1iW2" title="Share-based compensation, description">Vesting terms for options granted to employees and consultants during the six months ended June 30, 2021 included the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement. The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant. The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zB0Jd7McoPAk" title="Weighted-average fair value of options granted">4.96</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtYp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zlk1CywA8Bj4" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z3m5sBgvBRMi" title="Expected volatility">69</td><td style="text-align: left">%</td> </tr> <tr style="background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zlO3FujtacG5" title="Risk-free interest rate, minimum">0.39-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zRRqxcTP9Yrl" title="Risk-free interest rate, maximum">0.45</td><td style="text-align: left">%</td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z1NACdIrrAH8" title="Dividend yield">-</td><td style="text-align: left"> </td> </tr> </table> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxVIqmhvyU0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at June 30, 2021: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="padding-bottom: 1.5pt; text-align: left; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Range of Exercise Prices</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number Outstanding</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number Exercisable</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 15%; font-weight: bold">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zPeLVyjAwXy7" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zZGIEld1pYV1" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zNHIwhZUlGc7" style="width: 13%; text-align: right" title="Number of Options Outstanding">760,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWgTC0MyXQX6" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zZY6A0xbhW6i" style="width: 13%; text-align: right" title="Weighted Average Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zPCuVJz8SWz2" style="width: 13%; text-align: right" title="Number Exercisable">755,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBmKysTOeAf4" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z37QzuBSbt1i" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zU6pUWTUiNO2" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zj7tbmC3BOi9" style="text-align: right" title="Number of Options Outstanding">506,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKOeSaFGz872" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxMzhhOMEGe3" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfcsFBZKbaw3" style="text-align: right" title="Number Exercisable">449,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zMcdULop2GL2" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdmAIsR2UuYb" title="Range of Exercise Prices, minimum">5.49 - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8TD0Nqx7SQk" title="Range of Exercise Prices, maximum">6.36</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPH66h9N3w0j" style="text-align: right" title="Number of Options Outstanding">470,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zG2IK7Eg1Vt2" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuzMjYbsY13j" style="text-align: right" title="Weighted Average Exercise Price">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zP30hsYYOBuh" style="text-align: right" title="Number Exercisable">348,128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhqnHeSvZZc6" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.14</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zDwepQzksBO" title="Range of Exercise Prices, minimum">6.64 - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPaeRcfU7Jmh" title="Range of Exercise Prices, maximum">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPBWDKGsvVU4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">1,313,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJsxw4Rvyy7l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">4.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMpgnMWf4px4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">7.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zABuC0e6WfJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">779,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCHiBtz4ZHM4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">$1.47 - $8.99</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630_zoSLIgYyPWwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,050,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zAunoKrAxY92" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630_z8vGgDyzCK48" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630_z7f3d9vja9ua" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">2,333,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630_zhvlg0pclT0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of June 30, 2021, there was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan">2,012 of total unrecognized compensation expense related to unvested stock options granted under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zQSt74QopKU4" title="Weighted-average period for recognition">5.17 years. The stock-based compensation for all stock options was $569 and $1,021 during the three and six months ended June 30, 2021, respectively. The intrinsic value of options exercised during the three and six months ended June 30, 2021 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20210401__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zk2PqT3QGcm6" title="Intrinsic value of options exercised">14 and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Intrinsic value of options exercised">77, respectively. Restricted Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. During the six months ended June 30, 2021, <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmDnBIwISl61" title="Shares issued of restricted common stock, shares">300,000 RSUs with a fair market value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxVARVRBWJVg" title="Number of restrcited shares, value">2,670 were issued to certain employees; the RSUs vest in full on the third anniversary of the grant date. During the six months ended June 30, 2021, the Company’s board of directors were granted <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYyVsrPMVm2">38,576 RSUs with a fair market value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwja9Y9sn3k2">400 which vest in equal quarterly installments over one year. <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuHRgOHrxmlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the six months ended June 30, 2021 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">RSUs unvested - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxl5guAGKfT9" style="width: 22%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,601,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgyV4SCwzPAg" style="width: 22%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znRQ3Jl1R6V" style="text-align: right" title="Number of RSUs granted">338,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2oB2LtGR3af" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">9.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMbaBJmziqAb" style="text-align: right" title="Number of RSUs vested">(1,243,009</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znf5JrR2Oyti" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">2.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpJjsmU4YbK9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6oOWRfqzuae" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYmqYo0BEAg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">697,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVO2afBg2yt8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">7.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of June 30, 2021, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20210630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan">3,606, which is expected to be recognized over a weighted-average period of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zTZcW8nfxO0e" title="Weighted-average period for recognition">1.74 years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and six months ended June 30, 2021 was $481 and $827, respectively. Warrants From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements. A summary of warrant activity for the six months ended June 30, 2021 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxhouvr5fiX" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zIZZsJixLbl9" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxJMAXjrgRTc" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zwxHudREMqr" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">(406,539</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePriceGranted_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9n3zipI2Hzj" style="text-align: right" title="Weighted Avg. Exercise Price, Granted">2.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuDuWtCRMZGc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjTj5nQHdRfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">373,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyn1g9Tux0td" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBTcL70c1TH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years">3.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants outstanding and exercisable as of June 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">7/19/2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zGgG2UCRNu3a" style="width: 14%; text-align: right" title="Warrants Outstanding">373,847</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zRyucT9SPivb" style="width: 14%; text-align: right" title="Exercise Price">2.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zGWBskwnSr87" title="Expiration Date">7/19/2024</td></tr> </table> Subsidiary Stock-Based Transactions The Company recognized $28 and $85 in stock-based compensation expense related to subsidiary stock options during the three and six months ended June 30, 2021, respectively. Stock-Based Compensation Summary <p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z1tB1UhVuSgl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="text-align: center; font-weight: bold; vertical-align: bottom">For the Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_znNtN5jejKi3" style="width: 10%; text-align: right" title="Stock-based Compensation">923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z6IXp29VSIjg" style="width: 10%; text-align: right" title="Stock-based Compensation">436</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zwwW5ffBMh5g" style="width: 10%; text-align: right" title="Stock-based Compensation">1,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zb7R9ljnPhCc" style="width: 10%; text-align: right" title="Stock-based Compensation">872</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employees - R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zoACUNMbExl3" style="text-align: right" title="Stock-based Compensation">55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_znz6dDi6gPj7" style="text-align: right" title="Stock-based Compensation">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zil3INvDpoa" style="text-align: right" title="Stock-based Compensation">55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zbOabDbcDRQ1" style="text-align: right" title="Stock-based Compensation">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z9mLr71xRDn" style="text-align: right" title="Stock-based Compensation">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zFkAk5digAbg" style="text-align: right" title="Stock-based Compensation">96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zt2vyTxydUfh" style="text-align: right" title="Stock-based Compensation">200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zteyIT49i0Gf" style="text-align: right" title="Stock-based Compensation">193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_z7m1CqBZApIi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_z8rfBlIbJXZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_zWswGzZQCbb7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_zRrNdOvOJI1e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630_z4KzxjuwRRZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630_zUdo0tiAVH4j" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630_zwUd8qcP9Uga" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,933</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_z7ACxWwhIb82" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,161</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5000000

0.001

440000

0.001

25.00

10655000

Series B Preferred Stock was not convertible into our common stock, had no voting rights

0.0950

25.00

0.001

440000

25.00

11127

472000

311369

406539

1.79

3.75

16613

1.70

4.29

48000

715871

1050000

334129

2760000

100168

157500

57332

468000

35510

6000000

3967251

A summary of stock option activity under the Plans for the six months ended June 30, 2021 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="vertical-align: bottom; text-align: center"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of Shares</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="vertical-align: bottom; text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 36%">Options outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zjBWYvDgc013" style="width: 12%; text-align: right" title="Number of shares, Outstanding, Beginning balance">3,030,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zEaNjY1v33jc" style="width: 12%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zcz0bwciuise" style="text-align: right" title="Number of shares, Options granted">67,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zoYmQMgrLvdk" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zkyUeNqWgCaf" style="text-align: right" title="Number of shares, Options exercised">(16,613</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFr8WgubsPBl" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">2.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options cancelled/forfeited</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zpV2X8KrI1P" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(29,945</td><td style="text-align: left">)</td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGqRUSzsG6Ff" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">5.32</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td>Options outstanding - June 30, 2021</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zvafLl6U5wp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,050,475</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgaCP7cCwt8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.50</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zf7hzw3Qabod" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.28</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">11,555</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">Options exercisable</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z77ESRmA9e27" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">2,333,132</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zstIei30cAEg" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">5.01</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRywPgAyg7Ud" title="Weighted Avg. Remaining Contractual Life, Options exercisable">4.85</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">9,985</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Options vested and expected to vest</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGMFGMhDT3x" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,978,866</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8SRY2aULnd6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.46</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPCOzp1DNVQl" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.25</td><td style="text-align: left"> </td><td> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pn3n3" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">11,399</td><td style="text-align: left"> </td></tr> </table>

3030033

5.43

67000

8.07

16613

2.99

29945

5.32

3050475

5.50

P5Y3M10D

11555000

2333132

5.01

P4Y10M6D

9985000

2978866

5.46

P5Y3M

11399000

9.29

P10Y

Vesting terms for options granted to employees and consultants during the six months ended June 30, 2021 included the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.

The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zB0Jd7McoPAk" title="Weighted-average fair value of options granted">4.96</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtYp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zlk1CywA8Bj4" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z3m5sBgvBRMi" title="Expected volatility">69</td><td style="text-align: left">%</td> </tr> <tr style="background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zlO3FujtacG5" title="Risk-free interest rate, minimum">0.39-<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zRRqxcTP9Yrl" title="Risk-free interest rate, maximum">0.45</td><td style="text-align: left">%</td> </tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20210101__20210630__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z1NACdIrrAH8" title="Dividend yield">-</td><td style="text-align: left"> </td> </tr> </table>

4.96

P6Y1M9D

0.69

0.0039

0.0045

-0

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxVIqmhvyU0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at June 30, 2021: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr> <td style="padding-bottom: 1.5pt; text-align: left; font-size: 12pt"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Range of Exercise Prices</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number Outstanding</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Number Exercisable</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">Weighted Average Exercise Price</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; width: 15%; font-weight: bold">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zPeLVyjAwXy7" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zZGIEld1pYV1" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zNHIwhZUlGc7" style="width: 13%; text-align: right" title="Number of Options Outstanding">760,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zWgTC0MyXQX6" style="width: 13%; text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zZY6A0xbhW6i" style="width: 13%; text-align: right" title="Weighted Average Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zPCuVJz8SWz2" style="width: 13%; text-align: right" title="Number Exercisable">755,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBmKysTOeAf4" style="width: 13%; text-align: right" title="Weighted Average Exercisable Exercise Price">2.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z37QzuBSbt1i" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zU6pUWTUiNO2" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zj7tbmC3BOi9" style="text-align: right" title="Number of Options Outstanding">506,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zKOeSaFGz872" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zxMzhhOMEGe3" style="text-align: right" title="Weighted Average Exercise Price">3.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zfcsFBZKbaw3" style="text-align: right" title="Number Exercisable">449,872</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zMcdULop2GL2" style="text-align: right" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zdmAIsR2UuYb" title="Range of Exercise Prices, minimum">5.49 - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_z8TD0Nqx7SQk" title="Range of Exercise Prices, maximum">6.36</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zPH66h9N3w0j" style="text-align: right" title="Number of Options Outstanding">470,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zG2IK7Eg1Vt2" style="text-align: right" title="Weighted Average Remaining Contractual Life in Years">6.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zuzMjYbsY13j" style="text-align: right" title="Weighted Average Exercise Price">6.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zP30hsYYOBuh" style="text-align: right" title="Number Exercisable">348,128</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zhqnHeSvZZc6" style="text-align: right" title="Weighted Average Exercisable Exercise Price">6.14</td><td style="text-align: left"> </td></tr> <tr style="background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zDwepQzksBO" title="Range of Exercise Prices, minimum">6.64 - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPaeRcfU7Jmh" title="Range of Exercise Prices, maximum">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zPBWDKGsvVU4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding">1,313,241</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zJsxw4Rvyy7l" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">4.93</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zMpgnMWf4px4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price">7.86</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zABuC0e6WfJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable">779,924</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCHiBtz4ZHM4" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">7.96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">$1.47 - $8.99</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20210630_zoSLIgYyPWwf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding">3,050,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zAunoKrAxY92" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years">5.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210630_z8vGgDyzCK48" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price">5.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20210630_z7f3d9vja9ua" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">2,333,132</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20210630_zhvlg0pclT0c" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price">5.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1.47

2.60

760318

P5Y1M17D

2.06

755208

2.06

2.76

4.66

506566

P5Y2M19D

3.98

449872

3.98

5.49

6.36

470350

P6Y7M2D

6.12

348128

6.14

6.64

8.99

1313241

P4Y11M4D

7.86

779924

7.96

1.47

8.99

3050475

P5Y3M10D

5.50

2333132

5.01

2012000

P5Y2M1D

569000

1021000

14000

77000

300000

2670000

38576

400000

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zuHRgOHrxmlb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">A summary of the Company’s RSU activity and related information for the six months ended June 30, 2021 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">RSUs unvested - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxl5guAGKfT9" style="width: 22%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,601,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgyV4SCwzPAg" style="width: 22%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">3.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znRQ3Jl1R6V" style="text-align: right" title="Number of RSUs granted">338,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2oB2LtGR3af" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">9.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMbaBJmziqAb" style="text-align: right" title="Number of RSUs vested">(1,243,009</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znf5JrR2Oyti" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">2.24</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpJjsmU4YbK9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6oOWRfqzuae" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYmqYo0BEAg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">697,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20210630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVO2afBg2yt8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">7.61</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1601509

3.14

338576

9.07

1243009

2.24

697076

7.61

3606000

P1Y8M26D

481000

827000

A summary of warrant activity for the six months ended June 30, 2021 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxhouvr5fiX" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zIZZsJixLbl9" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zxJMAXjrgRTc" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zwxHudREMqr" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">(406,539</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePriceGranted_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z9n3zipI2Hzj" style="text-align: right" title="Weighted Avg. Exercise Price, Granted">2.16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuDuWtCRMZGc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zjTj5nQHdRfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">373,847</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pid_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zyn1g9Tux0td" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.08</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zBTcL70c1TH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years">3.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

780386

2.12

406539

2.16 373847 2.08 P3Y18D Warrants outstanding and exercisable as of June 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Series</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">7/19/2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zGgG2UCRNu3a" style="width: 14%; text-align: right" title="Warrants Outstanding">373,847</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zRyucT9SPivb" style="width: 14%; text-align: right" title="Exercise Price">2.08</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 14%; text-align: right"><span id="xdx_905_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zGWBskwnSr87" title="Expiration Date">7/19/2024</td></tr> </table> 2017-07-19

373847

2.08

2024-07-19

28000

85000

<p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z1tB1UhVuSgl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended</td><td style="text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="text-align: center; font-weight: bold; vertical-align: bottom">For the Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_znNtN5jejKi3" style="width: 10%; text-align: right" title="Stock-based Compensation">923</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z6IXp29VSIjg" style="width: 10%; text-align: right" title="Stock-based Compensation">436</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zwwW5ffBMh5g" style="width: 10%; text-align: right" title="Stock-based Compensation">1,678</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zb7R9ljnPhCc" style="width: 10%; text-align: right" title="Stock-based Compensation">872</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employees - R&D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zoACUNMbExl3" style="text-align: right" title="Stock-based Compensation">55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_znz6dDi6gPj7" style="text-align: right" title="Stock-based Compensation">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zil3INvDpoa" style="text-align: right" title="Stock-based Compensation">55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--EmployeesResearchAndDevelopmentMember_zbOabDbcDRQ1" style="text-align: right" title="Stock-based Compensation">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_z9mLr71xRDn" style="text-align: right" title="Stock-based Compensation">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zFkAk5digAbg" style="text-align: right" title="Stock-based Compensation">96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zt2vyTxydUfh" style="text-align: right" title="Stock-based Compensation">200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_zteyIT49i0Gf" style="text-align: right" title="Stock-based Compensation">193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_z7m1CqBZApIi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_z8rfBlIbJXZ5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_zWswGzZQCbb7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--ConsultantsSellingGeneralAndAdministrativeMember_zRrNdOvOJI1e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based Compensation">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630_z4KzxjuwRRZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630_zUdo0tiAVH4j" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">628</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630_zwUd8qcP9Uga" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,933</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_z7ACxWwhIb82" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based Compensation">1,161</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

923000

436000

1678000

872000

55000

100000

96000

200000

193000

96000

1078000

628000

1933000

1161000

<p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIgJg3Qyzskb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">NOTE 15. COMMITMENTS AND CONTINGENCIES Legal Novel Drug Solutions et al. In April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively “NDS”) filed a lawsuit against the Company in the U.S. District Court of Delaware asserting various claims, including breach of contract. The claims stem from an asset purchase agreement between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added claims related to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all but two claims, leaving only claims related to the scope and performance of the post-termination obligations to be litigated. Trial is currently set to begin in November 2021. NDS is seeking damages, interest, attorneys’ fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. John Erick et al. In January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick. In April 2018, Erick filed an amendment to the lawsuit, naming the Company as a co-defendant. In September 2018, co-defendant Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”). The cross-complaint seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October 2018. The case is currently in the discovery phase. Trial is currently set to begin October 2021. Erick is seeking unspecified damages, interest, attorneys’ fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. The Company’s insurance carrier has reserved its rights to seek contribution from the Company if the plaintiffs prevail on certain claims which the carrier alleges are uncovered. The Company believes the policy covers all claims. Nonetheless, the Company cannot predict the eventual outcome of this litigation, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. General and Other In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Indemnities In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Klarity License Agreement – Related Party The Company entered into a license agreement in April 2017 and as amended in April 2018, (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity designed to protect and rehabilitate the ocular surface (the “Klarity Product”). <span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember" title="Royalty payment description">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pn3n3" title="Royalty payments">50 upon execution of the Klarity License Agreement, (ii) a second payment of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pn3n3" title="Royalty payments">50 following the first $<span id="xdx_906_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pn3n3" title="Sales revenue net">50 in net sales of the Klarity Product; and (iii) a final payment of $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pn3n3" title="Royalty payments">50 following the first $<span id="xdx_909_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pn3n3" title="Sales revenue net">100 in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Payments totaling $35 and $70 were made during the three and six months ended June 30, 2021, respectively. Payments totaling $<span id="xdx_90F_ecustom--MilestonePaymentsOnPayables_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zkfXV73m5su">0 and $<span id="xdx_906_ecustom--MilestonePaymentsOnPayables_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_ziC6G07OOk1i">55 were made during the three and six months ended June 30, 2020, respectively. Royalty expense of $<span id="xdx_904_eus-gaap--RoyaltyExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zYJIxs95LrCh" title="Royalty expense">44 and $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z6J4pcEA1wFl" title="Royalty expense">79 was incurred during the three and six months ended June 30, 2021, respectively, and $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_pn3n3_c20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_z3x30jaY3VVc" title="Accounts payable">44 is included in accounts payable to Dr. Lindstrom as of June 30, 2021. Royalty expense of $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zbQGPREHJy49" title="Royalty expense">27 and $<span id="xdx_901_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember_zms59DSRnCD7" title="Royalty expense">56 was incurred during the three and six months ended June 30, 2020, respectively. Injectable Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”). Under the terms of the Lindstrom APA, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember" title="Royalty payment description">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_pn3n3" title="Royalty payments">33 upon execution of the Lindstrom APA. Dr. Lindstrom was paid $<span id="xdx_907_ecustom--MilestonePaymentInCash_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zt7UO33L0Mjf" title="Milestone payment in cash">7 and $<span id="xdx_905_ecustom--MilestonePaymentInCash_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_z9LuYgaAeEG3" title="Milestone payment in cash">14 in cash during the three and six months ended June 30, 2021, respectively. Dr. Lindstrom was paid $<span id="xdx_901_ecustom--MilestonePaymentInCash_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zxG4OfXRdWdi" title="Milestone payment in cash">0 and $<span id="xdx_904_ecustom--MilestonePaymentInCash_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zYg1Z2tFiwL1" title="Milestone payment in cash">7 in cash during the three and six months ended June 30, 2020, respectively. The Company incurred royalty expense of $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn3n3_c20210401__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zgMNaiPi5sy3" title="Royalty expense">7 and $<span id="xdx_904_eus-gaap--RoyaltyExpense_pn3n3_c20210101__20210630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zWKMS9MLVO75" title="Royalty expense">14 and $<span id="xdx_902_eus-gaap--RoyaltyExpense_pn3n3_c20200401__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_ziiJkLNW55k1" title="Royalty expense">4 and $<span id="xdx_900_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20200630__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember_zGdoLYxCOwpi" title="Royalty expense">42 related to the Lindstrom APA during the three and six months ended June 30, 2021, and 2020, respectively. Eyepoint Commercial Alliance Agreement In August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the United States. Pursuant to the Dexycu Agreement, Eyepoint will pay the Company a fee calculated based on the quarterly sales of DEXYCU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the Dexycu Agreement, the Company shall use commercially reasonable efforts to promote and market DEXYCU in the U.S. Subject to early termination, the Dexycu Agreement expires on August 1, 2025, subject to specified notice periods and specified limitations, either party may terminate the Dexycu Agreement in the event of (i) uncured material breach by the other party or (ii) if DEXYCU ceases to have “pass-through” payment status. In addition, subject to certain limitations, the Company may terminate the Dexycu Agreement (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change of control. Eyepoint may terminate the Dexycu Agreement, subject to specified notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three and six months ended June 30, 2021, the Company recorded $<span id="xdx_907_eus-gaap--SalesCommissionsAndFees_pn3n3_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--EyepointCommercialAllianceAgreementMember_zhdrHIJe7kf6" title="Commission expense incurred">827 and $<span id="xdx_907_eus-gaap--SalesCommissionsAndFees_pn3n3_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--EyepointCommercialAllianceAgreementMember_zEiVFlabF48e" title="Commission expense incurred">1,312, respectively, in commission revenues related to the Dexycu Agreement. Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations to provide exclusive and non-exclusive sales and marketing representation services to Harrow in select geographies in the U.S. in connection with the Company’s ophthalmic pharmaceutical compounded formulations or related products. Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to <span id="xdx_90B_ecustom--CommissionPaymentsPercentage_pid_dp_c20210101__20210630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_z1aVSzmj00qe" title="Commission payments percentage">10% - <span id="xdx_90F_ecustom--CommissionPaymentsPercentage_pid_dp_c20210101__20210630__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_zLg2UGmtUeO3" title="Commission payments percentage">14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make periodic milestone payments to certain organizations in shares of the Company’s restricted common stock if net sales in the assigned territory reach certain future levels by the end of their terms. Commission expenses of $1,032 and $1,836 and $318 and $921 were incurred under these agreements during the three and six months ended June 30, 2021, and 2020, respectively. Asset Purchase, License and Related Agreements The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. Royalty expenses of $261 and $493 and $117 and $261 were incurred under these agreements for the three and six months ended June 30, 2021 and 2020, respectively, and $272 and $431 are included in accounts payable at June 30, 2021 and 2020, respectively. Mayfield Pharmaceuticals MAY-66 License Termination In May 2021, Mayfield terminated the License Agreement (the “TGV License”) with TGV-Health, LLC and affiliated entities (collectively, “TGV”), pursuant to which it acquired intellectual property rights for use in the women’s health field, related to Mayfield’s proprietary drug candidate MAY-66. Concurrent with the termination, TGV returned to Mayfield <span id="xdx_90B_ecustom--SharesReturned_pid_c20210501__20210531__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zEUKRB7Pvaad" title="Shares returned">300,000 shares of Mayfield’s common stock, constituting all of the equity held by TGV. Mayfield has no outstanding or remaining obligations under the TGV License. Mayfield Pharmaceuticals MAY-44 APA Termination In May 2021, Mayfield and Harrow terminated their asset purchase agreement dated January 2020 for intellectual property rights associated with Mayfield’s drug candidate MAY-44 with Elle Pharmaceutical LLC (the “MAY-44 APA”). As part of the termination, Mayfield re-acquired <span id="xdx_90E_ecustom--SharesReacquired_pid_c20210501__20210531__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zofC6Yq9Utgf" title="Shares reacquired">350,000 shares of its common stock from Elle. Mayfield has no outstanding or remaining obligations related to the MAY-44 APA. Stowe License Termination In May 2021, Stowe terminated the License Agreement (the “Stowe License”) with TGV, pursuant to which it acquired intellectual property rights for use in the ophthalmic field, related to Stowe’s proprietary drug candidate STE-006. Concurrent with the termination, TGV returned to Stowe <span id="xdx_906_ecustom--SharesReturned_pid_c20210501__20210531__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsMember__us-gaap--TypeOfArrangementAxis__custom--StoweLicenseAgreementMember_zy1b6pyRoZt4">1,750,000 shares of Stowe’s common stock, constituting all of the equity held by TGV. Stowe has no outstanding or remaining obligations under the Stowe License.

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold.

50000

100000 35000 70000 0 55000

44000

79000

44000

27000

56000

the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.

33000

7000 14000 0 7000

7000

14000

4000

42000

827000

1312000

0.10 0.14

1032000

1836000

318000

921000

In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors.

261000

493000

117000

261000

272000

431000

300000 350000 1750000

NOTE 16. SEGMENT INFORMATION AND CONCENTRATIONS Management evaluates performance of the Company based on operating segments. Segment performance for its two operating segments is based on segment contribution. The Company’s reportable segments consist of (i) its commercial stage pharmaceutical business known as ImprimisRx; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other select revenues and operating expenses including R&D expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total assets including capital expenditures.</td></tr> </table> The Company defines segment net revenues as pharmaceutical compounded drug sales, licenses, commissions and other revenue derived from related agreements. Cost of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses. Selling, general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs, professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which are general in nature and attributable to the segment. <p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zFSOK1CDKM6l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2021: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">18,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">18,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zaYLIspYPWy2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zIRpKjHbRns3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zMMvKRRv7p2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">13,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">13,717</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,422</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">104</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">7,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(104</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">7,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,662</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AdjustmentForAmortization_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">4,169</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">For the Six Months Ended </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">33,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">33,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zexeKt4IghWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(8,187</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zmThdVtE42Xd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z0G6j30eEjOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(8,187</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">25,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">25,390</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">12,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">12,193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">322</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">12,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(117</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">12,758</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">5,015</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">578</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">79</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">7,086</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">For the Three Months Ended June 30, 2020 </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zAaRARHVr8Me" style="width: 10%; text-align: right" title="Total revenues">8,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zjkbkN1jEd0f" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zXJ7Upg5fJwb" style="width: 10%; text-align: right" title="Total revenues">8,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z2wtfPIXSwdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zj766cX2iTUc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4TdqUe5NcU3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_ztkKq2bf2Hq4" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z0katEAsh3Kk" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxSlH5cFAiMa" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zAp2lwK4mM5k" style="text-align: right" title="Selling, general and administrative">4,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_ziIz8U3DNFal" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zzdVMsIrxng5" style="text-align: right" title="Selling, general and administrative">4,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zffcuF3SZb3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">497</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zlHlLsWgKoa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zp3jl4A6gAw3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zA2shHFJe751" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zaX50hFfTUT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(89</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zR50Bw964NWb" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zMka9rgml2Lf" style="text-align: right" title="Operating income (loss)">2,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zll5LLl8uPke" style="text-align: right" title="Operating income (loss)">206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AdjustmentForAmortization_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zpRLuIl1ZEue" style="text-align: right" title="Amortization">43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__custom--AssetSalesAndImpairmentsNetMember_zy5E3aof4Yk6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating income (loss)">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLbqmVnsZB9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(3,210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">For the Six Months Ended June 30, 2020 </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">Pharmaceutical</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">Pharmaceutical</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Compounding</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">19,877</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">19,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zXEEGD0nU0Be" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zx4ALxYNGP6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zqWhgTtGS4vi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">11,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">11,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">540</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">57</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,269</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">3,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AdjustmentForAmortization_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__custom--AssetSalesAndImpairmentsNetMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating income (loss)">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(3,838</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues are attributed to the U.S. All long-lived assets at June 30, 2021 and December 31, 2020 were located in the U.S. Concentrations The Company has two products that each comprised more than 10% of total revenues during the quarter. These products collectively accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember_zsaZudm1Hgrd" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--TwoProductConcentrationRiskMember_zICt7aDkRkpe" title="Concentration risk percentage">36% of revenues during each of the three and six months ended June 30, 2021. The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales for the three and six months ended June 30, 2021 and 2020. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210401__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zu8MmJ0E4CR4" title="Concentration risk percentage">85% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zBKOwLUuofqc" title="Concentration risk percentage">79% of active pharmaceutical ingredient purchases during the three and six months ended June 30, 2021, respectively, and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200401__20200630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zlEJz2Fvj5Y9" title="Concentration risk percentage">60% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200101__20200630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis__custom--ThreeMainSuppliersMember_zioFR0tMU3Ni" title="Concentration risk percentage">70% of active pharmaceutical ingredient purchases during the three and six months ended June 30, 2020, respectively.

two

<p id="xdx_89A_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zFSOK1CDKM6l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and six months ended June 30, 2021: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">For the Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">18,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">18,134</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zaYLIspYPWy2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zIRpKjHbRns3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zMMvKRRv7p2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">13,717</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GrossProfit_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">13,717</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,422</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">104</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">216</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">7,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(104</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--SegmentContribution_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">7,079</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,662</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">209</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AdjustmentForAmortization_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_c20210401__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">4,169</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">For the Six Months Ended </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">June 30, 2021</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">33,577</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">33,577</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zexeKt4IghWb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(8,187</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zmThdVtE42Xd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z0G6j30eEjOa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(8,187</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">25,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">25,390</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">12,193</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Selling, general and administrative">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">12,193</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">322</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">12,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(117</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SegmentContribution_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">12,758</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">5,015</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">578</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization">79</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating income</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20210101__20210630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">7,086</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">For the Three Months Ended June 30, 2020 </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">ImprimisRx</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Pharmaceutical Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zAaRARHVr8Me" style="width: 10%; text-align: right" title="Total revenues">8,060</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zjkbkN1jEd0f" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zXJ7Upg5fJwb" style="width: 10%; text-align: right" title="Total revenues">8,060</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_z2wtfPIXSwdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zj766cX2iTUc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4TdqUe5NcU3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_ztkKq2bf2Hq4" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_z0katEAsh3Kk" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zxSlH5cFAiMa" style="text-align: right" title="Gross profit">4,856</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zAp2lwK4mM5k" style="text-align: right" title="Selling, general and administrative">4,598</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_pdn3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_ziIz8U3DNFal" style="text-align: right" title="Selling, general and administrative">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zzdVMsIrxng5" style="text-align: right" title="Selling, general and administrative">4,641</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zffcuF3SZb3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">497</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zlHlLsWgKoa2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zp3jl4A6gAw3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">543</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zA2shHFJe751" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(239</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zaX50hFfTUT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(89</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--SegmentContribution_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zR50Bw964NWb" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zMka9rgml2Lf" style="text-align: right" title="Operating income (loss)">2,270</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zll5LLl8uPke" style="text-align: right" title="Operating income (loss)">206</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AdjustmentForAmortization_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zpRLuIl1ZEue" style="text-align: right" title="Amortization">43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__custom--AssetSalesAndImpairmentsNetMember_zy5E3aof4Yk6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating income (loss)">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_pn3n3_c20200401__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zFLbqmVnsZB9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(3,210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="11" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">For the Six Months Ended June 30, 2020 </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">Pharmaceutical</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">Pharmaceutical</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Compounding</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Drug Development</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">19,877</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="width: 22%; text-align: right" title="Total revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 10%; text-align: right" title="Total revenues">19,877</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_zXEEGD0nU0Be" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CostOfGoodsAndServicesSold_iN_pdn3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zx4ALxYNGP6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zqWhgTtGS4vi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(6,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pdn3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">13,047</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="text-align: right" title="Selling, general and administrative">11,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">11,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">540</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">57</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">597</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Segment contribution</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--ImprimisRxMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,269</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(144</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--SegmentContribution_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">1,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">3,957</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AdjustmentForAmortization_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Asset sales and impairments, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__custom--AssetSalesAndImpairmentsNetMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Operating income (loss)">363</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Operating loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20200101__20200630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(3,838</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

18134000

4417000

13717000

6422000

112000

104000

216000

7183000 -104000 7079000

2662000

209000

39000

4169000

33577000

8187000

25390000

12193000

322000

117000

439000

12875000 -117000 12758000

5015000

578000

79000

7086000

8060000

3204000

4856000

4598000

43000

4641000

497000

46000

543000

-239000 -89000 -328000

2270000

206000

43000

363000

-3210000

19877000

6830000

13047000

11238000

87000

11325000

540000

57000

597000

1269000 -144000 1125000

3957000

555000

88000

363000

-3838000

0.36

0.85

0.79

0.60

0.70

NOTE 17. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to June 30, 2021 through the filing date of this Quarterly Report. Based on its evaluation, no events other than those described below need to be disclosed. Sintetica Agreement In July 2021, the Company entered into a License and Supply Agreement (the “Sintetica Agreement”) with Sintetica S.A. (“Sintetica”), pursuant to which Sintetica granted the Company the exclusive license and marketing rights to its patented ophthalmic drug candidate (“AMP-100”) in the U.S. and Canada. Pursuant to the Sintetica Agreement, the Company will pay Sintetica a per unit transfer price to supply AMP-100, along with a per unit royalty for units sold. The Company is required to pay Sintetica up to $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_pn3n3_c20210701__20210731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember_z3UuWz9eiiq2" title="Royalty payments">18,000 in one-time milestone payments including a $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_pn3n3_c20210701__20210731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SinteticaAgreementMember__srt--StatementScenarioAxis__custom--DueWithinThirtyDaysMember_ziXWZeHqTAYk" title="Royalty payments">5,000 payment due within 30 days of signing the Sintetica Agreement and the balance of payments due upon achievement of certain regulatory and commercial milestones. Under the terms of the Sintetica Agreement, Sintetica will be responsible for regulatory filings for AMP-100 in the U.S. Subject to certain limitations, the term of the Sintetica Agreement is ten years, and allows for a ten-year extension if certain sales thresholds are met.

18000000

5000000